| The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase. | |
MedLine Citation:
|
PMID: 10932976 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The association of transforming growth factor-beta 1 (TGF-beta 1) with a matrix metalloproteinase (MMP) and a tissue inhibitor of metalloproteinase (TIMP), as well as myometrial invasion of endometrial cancer was studied. METHODS: The effects of TGF-beta 1 on cellular invasiveness, gelatinase activity, and expression of TIMP-1 were examined in 2 endometrial adenocarcinoma cell lines, KLE and Ishikawa. Plasma was obtained from 8 endometrial cancer patients with Stage-Ia disease, from 6 with Stage-Ib disease, and from 4 with Stage-Ic disease, and the levels of TGF-beta 1 were measured by enzyme immunoassays. The immunohistochemical expression of MMP-9, TIMP-1, TGF-beta 1, and TGF-beta receptor Type I in tumor tissue from the same patients also was detected. RESULTS: Invasiveness, gelatinase activity, and the expression of TIMP-1 were higher in KLE cells than in Ishikawa cells, and they were increased by treatment with rTGF-beta 1. The expression of TGF-beta receptor Type I was higher in KLE cells than in Ishikawa cells, which were unresponsive to exogenous TGF-beta 1. The plasma levels of TGF-beta 1 were greater in Stage-Ib and Stage-Ic patients than in Stage-Ia patients. MMP-9 and TGF-beta receptor Type I were expressed mainly in tumor cells, while TIMP-1 and TGF-beta 1 were localized in both tumor epithelial cells and stromal cells. MMP-9 and TIMP-1 were expressed only in Stage-Ib and Stage-Ic patients, although TGF-beta 1 and TGF-beta receptor Type I were ubiquitous. CONCLUSIONS: Myometrial invasion of endometrial cancers involves an increase in gelatinase activity, regulated to some extent by TGF-beta 1 in an autocrine or paracrine fashion. |
Authors:
|
H Yabushita; H Narumiya; K Hiratake; H Yamada; M Shimazu; K Sawaguchi; M Noguchi; M Nakanishi |
Related Documents
:
|
2139036 - Mechanism of activation of latent recombinant transforming growth factor beta 1 by plas... 9060836 - Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollag... 8023956 - Transforming growth factor-beta induces a chondroitin sulfate/dermatan sulfate proteogl... 1370796 - Transforming growth factor beta 1 inhibits gonadotropin action in cultured porcine sert... 6195256 - Regulation of the hapten-specific t cell response. i. preferential induction of hypores... 21561736 - The slam family member cd48 (slamf2) protects lupus-prone mice from autoimmune nephritis. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The journal of obstetrics and gynaecology research Volume: 26 ISSN: 1341-8076 ISO Abbreviation: J. Obstet. Gynaecol. Res. Publication Date: 2000 Jun |
Date Detail:
|
Created Date: 2000-08-17 Completed Date: 2000-08-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9612761 Medline TA: J Obstet Gynaecol Res Country: JAPAN |
Other Details:
|
Languages: eng Pagination: 163-70 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Aichi Medical University, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
chemistry,
enzymology,
pathology* Colonic Neoplasms / chemistry, pathology Endometrial Neoplasms / chemistry, enzymology, pathology* Female Gelatinases / metabolism Humans Immunohistochemistry Matrix Metalloproteinase 9 / analysis Matrix Metalloproteinases / metabolism* Myometrium / pathology* Neoplasm Invasiveness* Neoplasm Staging Receptors, Transforming Growth Factor beta / analysis Tissue Inhibitor of Metalloproteinase-1 / metabolism Transforming Growth Factor beta / analysis, blood*, pharmacology Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Transforming Growth Factor beta; 0/Tissue Inhibitor of Metalloproteinase-1; 0/Transforming Growth Factor beta; EC 3.4.24.-/Gelatinases; EC 3.4.24.-/Matrix Metalloproteinases; EC 3.4.24.35/Matrix Metalloproteinase 9 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Laparoscopic management of heterotopic pregnancy: a review.
Next Document: Dimeric inhibin A as a fourth marker for Down's syndrome maternal serum screening in native Japanese...